STIM vs. PDEX, DRIO, ICAD, TTOO, PYPD, PROF, DCTH, TLSI, CVRX, and NPCE
Should you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Pro-Dex (PDEX), DarioHealth (DRIO), iCAD (ICAD), T2 Biosystems (TTOO), PolyPid (PYPD), Profound Medical (PROF), Delcath Systems (DCTH), TriSalus Life Sciences (TLSI), CVRx (CVRX), and NeuroPace (NPCE). These companies are all part of the "surgical & medical instruments" industry.
Pro-Dex (NASDAQ:PDEX) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 42.6% of Pro-Dex shares are owned by insiders. Comparatively, 9.8% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Neuronetics has a consensus target price of $8.00, suggesting a potential upside of 257.14%. Given Pro-Dex's higher possible upside, analysts clearly believe Neuronetics is more favorable than Pro-Dex.
Pro-Dex received 22 more outperform votes than Neuronetics when rated by MarketBeat users. However, 68.48% of users gave Neuronetics an outperform vote while only 60.91% of users gave Pro-Dex an outperform vote.
Pro-Dex has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Pro-Dex has a net margin of 4.13% compared to Pro-Dex's net margin of -37.61%. Neuronetics' return on equity of 6.50% beat Pro-Dex's return on equity.
In the previous week, Neuronetics had 1 more articles in the media than Pro-Dex. MarketBeat recorded 3 mentions for Neuronetics and 2 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.90 beat Neuronetics' score of 0.31 indicating that Neuronetics is being referred to more favorably in the news media.
Pro-Dex has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500.
Summary
Pro-Dex beats Neuronetics on 9 of the 17 factors compared between the two stocks.
Get Neuronetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuronetics Competitors List
Related Companies and Tools
